close

Gore PharmBIO Introduces 250mL, 500mL and 1L Protein Capture Devices With Protein A to Deliver Consistent Scalability and Increased Productivity Across Sizes

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Larger sizes demonstrate latest innovations in Gore’s chromatography device portfolio for mAb affinity purification solutions from process development to commercial scale

W. L. Gore & Associates, Inc. (“Gore”), a global materials science company, continues to build on its growing portfolio of protein capture devices with the introduction of its 250mL, 500mL and 1L GORE® Protein Capture Devices with Protein A. The offerings follow commercial availability of its 116mL and 232mL sizes introduced in mid 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230404005156/en/

GORE® Protein Capture Devices with Protein A (Photo: Business Wire)

GORE® Protein Capture Devices with Protein A (Photo: Business Wire)

With these new, larger capacity sizes, Gore continues to expand its GMP solutions, joining its current portfolio of 9mL, 58mL, 116mL, and 232mL devices. Additionally, Gore offers lab-scale sizes, 1.0mL and 3.5mL, for non-GMP applications. The three new larger offerings allow consistent scalability in pressure, elution width, and binding capacity, making tech transfer efficient across sizes. All of the devices use a unique membrane composite that provides high dynamic binding capacity and short residence time, resulting in increased throughput and productivity.

“The introduction of our new 250mL, 500mL, and 1L protein capture devices provides our biopharma customers with flexible and scalable solutions that are compatible with their existing capital,” said William Barrett, Ph.D., Product Specialist for Gore PharmBIO Products. “With these new sizes, Gore continues to offer leading membrane expertise for rapid antibody purification and addresses their GMP application needs.”

Key features of the 250mL, 500mL and 1L GORE® Protein Capture Devices with Protein A include:

  • High dynamic binding capacity (≥ 40 mg/mL) at short residence time (30 seconds)
  • Demonstrated ability to cycle over 100 times with CIP
  • Low delta column pressure over cycling
  • Consistent scalability across sizes
  • Low elution volumes
  • GMP-supported

Learn more about GORE® Protein Capture Devices with Protein A and get the latest information on upcoming events at www.gore.com/capturemoremAbs.

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 11,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $3.8 billion. For more information, visit gore.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  259.53
-2.90 (-1.11%)
AAPL  340.97
+4.33 (1.29%)
AMD  594.24
-13.86 (-2.28%)
BAC  54.58
+0.26 (0.48%)
GOOG  348.97
+1.11 (0.32%)
META  742.96
+24.29 (3.38%)
MSFT  541.15
+6.08 (1.14%)
NVDA  226.32
-2.96 (-1.29%)
ORCL  137.39
-4.01 (-2.84%)
TSLA  378.03
-4.67 (-1.22%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Starting at /week.